Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Sep;36(9):1864–1869. doi: 10.1128/aac.36.9.1864

Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci.

M C Ramos 1, M L Grayson 1, G M Eliopoulos 1, A S Bayer 1
PMCID: PMC192201  PMID: 1329632

Abstract

Infections with enterococci that are resistant to multiple antibiotics are an emerging clinical problem. We evaluated the antibiotic treatment of experimental enterococcal endocarditis caused by two strains with different mechanisms of penicillin resistance. Enterococcus faecalis HH-22 is resistant to aminoglycosides and penicillin on the basis of plasmid-mediated modifying enzymes; Enterococcus raffinosus SF-195 is susceptible to aminoglycosides but is resistant to penicillin on the basis of low-affinity penicillin-binding proteins. Animals infected with strain HH-22 received 5 days of treatment with the following: no treatment; daptomycin (20 mg/kg of body weight twice daily [b.i.d.], intramuscularly [i.m.]), vancomycin (20 mg/kg b.i.d., intravenously), or ampicillin (100 mg/kg three times daily, i.m.) plus gentamicin (2.5 mg/kg b.i.d. i.m.). Although vancomycin was superior to ampicillin-gentamicin (P less than 0.01), daptomycin was significantly better than all other treatment regimens (P less than 0.01) in reducing intravegetation enterococcal densities, although no vegetations were rendered culture negative by this agent. Animals infected with strain SF-195 received 5 days of no therapy, ampicillin, ampicillin-gentamicin, vancomycin, or daptomycin (all at the dosage regimens described above). Daptomycin, vancomycin, and ampicillin-gentamicin each lowered intravegetation enterococcal densities significantly better than did ampicillin monotherapy or no treatment (P less than 0.01); moreover, these three treatment regimens rendered significantly more vegetations culture negative than did ampicillin monotherapy or no treatment (P less than 0.05). Serum daptomycin levels remained above the MICs and MBCs for both enterococcal strains throughout the 12-h dosing interval used in the study. Daptomycin and vancomycin were both active in vivo in these models of experimental enterococcal endocarditis caused by penicillin-resistant strains, irrespective of the mechanism of resistance. This activity correlated with the unique cell wall sites of action of these agents (binding to lipoteichoic acid and pentapeptide precursor, respectively) compared with the sites of action of beta-lactams (penicillin-binding proteins). Beta-Lactamase production by strain HH-22 precluded in vivo efficacy with ampicillin-gentamicin combinations. In contrast, this combination was active in vivo against strain SF-195, which exhibited intermediate-level penicillin resistance (MIC, 32 micrograms/ml), likely reflecting the ability of high-dose ampicillin to achieve enough binding to low-affinity penicillin-binding proteins to cause augmented aminoglycoside uptake.

Full text

PDF
1864

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayer A. S., Tu J. Chemoprophylactic efficacy against experimental endocarditis caused by beta-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activity. Antimicrob Agents Chemother. 1990 Jun;34(6):1068–1074. doi: 10.1128/aac.34.6.1068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bayer A. S., Yih J., Hirano L. LY146032 compared with penicillin G in experimental aortic valve endocarditis caused by group G streptococci. Antimicrob Agents Chemother. 1988 Jan;32(1):141–143. doi: 10.1128/aac.32.1.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bush L. M., Boscia J. A., Kaye D. Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1988 Jun;32(6):877–881. doi: 10.1128/aac.32.6.877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bush L. M., Calmon J., Cherney C. L., Wendeler M., Pitsakis P., Poupard J., Levison M. E., Johnson C. C. High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections. Ann Intern Med. 1989 Apr 1;110(7):515–520. doi: 10.7326/0003-4819-110-7-515. [DOI] [PubMed] [Google Scholar]
  5. Canepari P., Boaretti M., Lleó M. M., Satta G. Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother. 1990 Jun;34(6):1220–1226. doi: 10.1128/aac.34.6.1220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Carrizosa J., Kaye D. Antibiotic synergism in enterococcal endocarditis. J Lab Clin Med. 1976 Jul;88(1):132–141. [PubMed] [Google Scholar]
  7. Grayson M. L., Eliopoulos G. M., Wennersten C. B., Ruoff K. L., Klimm K., Sapico F. L., Bayer A. S., Moellering R. C., Jr Comparison of Enterococcus raffinosus with Enterococcus avium on the basis of penicillin susceptibility, penicillin-binding protein analysis, and high-level aminoglycoside resistance. Antimicrob Agents Chemother. 1991 Jul;35(7):1408–1412. doi: 10.1128/aac.35.7.1408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hindes R. G., Willey S. H., Eliopoulos G. M., Rice L. B., Eliopoulos C. T., Murray B. E., Moellering R. C., Jr Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother. 1989 Jul;33(7):1019–1022. doi: 10.1128/aac.33.7.1019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ingerman M., Pitsakis P. G., Rosenberg A., Hessen M. T., Abrutyn E., Murray B. E., Levison M. E. beta-Lactamase production in experimental endocarditis due to aminoglycoside-resistant Streptococcus faecalis. J Infect Dis. 1987 Jun;155(6):1226–1232. doi: 10.1093/infdis/155.6.1226. [DOI] [PubMed] [Google Scholar]
  10. Kaye D. Changing pattern of infective endocarditis. Am J Med. 1985 Jun 28;78(6B):157–162. doi: 10.1016/0002-9343(85)90378-x. [DOI] [PubMed] [Google Scholar]
  11. Knox J. R., Pratt R. F. Different modes of vancomycin and D-alanyl-D-alanine peptidase binding to cell wall peptide and a possible role for the vancomycin resistance protein. Antimicrob Agents Chemother. 1990 Jul;34(7):1342–1347. doi: 10.1128/aac.34.7.1342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Leclercq R., Derlot E., Duval J., Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988 Jul 21;319(3):157–161. doi: 10.1056/NEJM198807213190307. [DOI] [PubMed] [Google Scholar]
  13. Miller M. H., el-Sokkary M. A., Feinstein S. A., Lowy F. D. Penicillin-induced effects on streptomycin uptake and early bactericidal activity differ in viridans group and enterococcal streptococci. Antimicrob Agents Chemother. 1986 Nov;30(5):763–768. doi: 10.1128/aac.30.5.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Murray B. E., Church D. A., Wanger A., Zscheck K., Levison M. E., Ingerman M. J., Abrutyn E., Mederski-Samoraj B. Comparison of two beta-lactamase-producing strains of Streptococcus faecalis. Antimicrob Agents Chemother. 1986 Dec;30(6):861–864. doi: 10.1128/aac.30.6.861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Murray B. E., Mederski-Samoraj B., Foster S. K., Brunton J. L., Harford P. In vitro studies of plasmid-mediated penicillinase from Streptococcus faecalis suggest a staphylococcal origin. J Clin Invest. 1986 Jan;77(1):289–293. doi: 10.1172/JCI112289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Oster S. E., Chirurgi V. A., Goldberg A. A., Aiken S., McCabe R. E. Ampicillin-resistant enterococcal species in an acute-care hospital. Antimicrob Agents Chemother. 1990 Sep;34(9):1821–1823. doi: 10.1128/aac.34.9.1821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Patterson J. E., Colodny S. M., Zervos M. J. Serious infection due to beta-lactamase-producing Streptococcus faecalis with high-level resistance to gentamicin. J Infect Dis. 1988 Nov;158(5):1144–1145. doi: 10.1093/infdis/158.5.1144. [DOI] [PubMed] [Google Scholar]
  18. Rhinehart E., Smith N. E., Wennersten C., Gorss E., Freeman J., Eliopoulos G. M., Moellering R. C., Jr, Goldmann D. A. Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med. 1990 Dec 27;323(26):1814–1818. doi: 10.1056/NEJM199012273232606. [DOI] [PubMed] [Google Scholar]
  19. Rice L. B., Eliopoulos G. M., Wennersten C., Goldmann D., Jacoby G. A., Moellering R. C., Jr Chromosomally mediated beta-lactamase production and gentamicin resistance in Enterococcus faecalis. Antimicrob Agents Chemother. 1991 Feb;35(2):272–276. doi: 10.1128/aac.35.2.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sapico F. L., Canawati H. N., Ginunas V. J., Gilmore D. S., Montgomerie J. Z., Tuddenham W. J., Facklam R. R. Enterococci highly resistant to penicillin and ampicillin: an emerging clinical problem? J Clin Microbiol. 1989 Sep;27(9):2091–2095. doi: 10.1128/jcm.27.9.2091-2095.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Wells V. D., Wong E. S., Murray B. E., Coudron P. E., Williams D. S., Markowitz S. M. Infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis. Ann Intern Med. 1992 Feb 15;116(4):285–292. doi: 10.7326/0003-4819-116-4-285. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES